Synonyms: 3-pentylbenzeneacetic acid | fezagepras | PBI-4050 | PBI4050
Compound class:
Synthetic organic
Comment: Setogepram (PBI-4050) is an orally active, synthetic analogue of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively [1]. it is a potentially novel first-in-class compound with significant antifibrotic and antiinflammatory activities that was being developed by Liminal BioSciences (formerly Prometic Life Sciences).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Gagnon L, Leduc M, Thibodeau JF, Zhang MZ, Grouix B, Sarra-Bournet F, Gagnon W, Hince K, Tremblay M, Geerts L et al.. (2018)
A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84. Am J Pathol, 188 (5): 1132-1148. [PMID:29454750] |
2. Li Y, Chung S, Li Z, Overstreet JM, Gagnon L, Grouix B, Leduc M, Laurin P, Zhang MZ, Harris RC. (2018)
Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight, 3 (10). [PMID:29769449] |